Starling Oncology, Inc.
STLNW- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $163.5K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Starling Oncology, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 15 | 16 | +1 |
| Shares | 4.35M | 4.49M | +139.4K (+3.2%) |
| Value | $406.9K | $806.9K | +$400.1K (+98.3%) |
New holders (3)
Institutions that held Starling Oncology, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 30,000 | $3.75K | 0.00% |
| FreeGulliver LLC | 18,500 | $2.31K | 0.00% |
| Bank of America Corp | 200 | $25 | 0.00% |
Sold out (2)
Institutions that held Starling Oncology, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Jefferies Financial Group Inc. | 95,000 | $8.73K |
| UBS Group AG | 1,034 | $88 |